4 min read
ASCO 2026: RAS Is No Longer Undruggable
For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes...
Veristat will attend the upcoming ASH Annual Meeting 2018 taking place in San Diego, California from Dec 1-4, 2018, the premier event in malignant and non-malignant hematology.
Veristat has guided clients through the conduct of more than 100 clinical trials and nearly 20 regulatory agency submissions for blood diseases. Our experience spans clinical development consulting, full clinical trial oversight, and regulatory submission preparation for rare genetic blood disorders and autoimmune blood diseases, as well as blood cancers.
Our experts, John Balser, and Barbara Balser, as well as Cindy Henderson and Shaheen Limbada, will be attending.
Schedule A Meeting:
Schedule a time to speak with Veristat at the event on how we can put our oncology clinical trial and regulatory submission experience to work for you. Fill out the form on the right.
Explore Our Key Related Services:
10 min read
Monthly FDA Guidance and Regulatory News Review - May 2026
Jun 12, 2026 Veristat Blog
This May 2026 regulatory update highlights multiple guidances issued by the FDA across cell and gene therapy, clinical...